Harmony Biosciences Holdings Inc (HRMY)

$33.92

+0.62

(+1.86%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $33.03
    $33.95
    $33.92
    downward going graph

    2.62%

    Downside

    Day's Volatility :2.71%

    Upside

    0.09%

    downward going graph
  • $18.61
    $39.27
    $33.92
    downward going graph

    45.14%

    Downside

    52 Weeks Volatility :52.61%

    Upside

    13.62%

    downward going graph

Returns

PeriodHarmony Biosciences Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
13.57%
6.5%
0.0%
6 Months
7.14%
7.1%
0.0%
1 Year
-6.2%
9.8%
0.0%
3 Years
24.63%
14.2%
-20.2%

Highlights

Market Capitalization
1.9B
Book Value
$9.07
Earnings Per Share (EPS)
2.32
PE Ratio
14.15
Wall Street Target Price
43.63
Profit Margin
22.3%
Operating Margin TTM
33.65%
Return On Assets TTM
16.3%
Return On Equity TTM
28.74%
Revenue TTM
617.5M
Revenue Per Share TTM
10.52
Quarterly Revenue Growth YOY
29.799999999999997%
Gross Profit TTM
354.4M
EBITDA
228.1M
Diluted Eps TTM
2.32
Quarterly Earnings Growth YOY
0.4
EPS Estimate Current Year
2.06
EPS Estimate Next Year
3.68
EPS Estimate Current Quarter
0.6
EPS Estimate Next Quarter
0.7

Analyst Recommendation

Buy
    78%Buy
    7%Hold
    14%Sell
Based on 14 Wall street analysts offering stock ratings for Harmony Biosciences Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 28.63%

Current $33.92
Target $43.63

Technicals Summary

Sell

Neutral

Buy

Harmony Biosciences Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
7.14%
7.14%
-6.2%
24.63%
-10.02%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
14.15
14.15
NA
2.06
0.29
0.16
NA
9.07
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
Buy
$1.9B
-10.02%
14.15
22.3%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Harmony Biosciences Holdings Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 168.41M → 154.61M (in $), with an average decrease of 8.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 26.60M → 38.33M (in $), with an average increase of 30.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 67.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 161.9%

Institutional Holdings

  • Valor Management LLC

    19.75%

  • BlackRock Inc

    10.43%

  • FMR Inc

    9.25%

  • Vanguard Group Inc

    6.39%

  • Vivo Capital, LLC

    4.59%

  • State Street Corporation

    2.28%

Company Information

patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.

Organization
Harmony Biosciences Holdings Inc
Employees
246
CEO
Mr. Jeffrey S. Aronin
Industry
Health Technology

Discover More

FAQs